An Open-Label, Dose-Ranging Study of Atomoxetine in Children with Attention Deficit Hyperactivity Disorder
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The goal of this study was to evaluate the tolerability and effectiveness of the experimental, noradrenergic specific reuptake inhibitor atomoxetine in the treatment of children with attention deficit hyperactivity disorder (ADHD). METHODS: This was an open, prospective, dose-ranging study of atomoxetine monotherapy in the treatment of 30 children with ADHD between the ages of 7 and 14 years. Atomoxetine was started at 10-20 mg/day and titrated weekly up to 90 mg over 11 weeks, depending on response and adverse effects. Twenty-two children completed the full 11 weeks. We assessed efficacy with weekly clinician and parent ratings of ADHD and oppositional symptoms and monitored adverse effects, laboratory findings, and cardiovascular parameters. RESULTS: Treatment with atomoxetine (mean final, total daily dose of 1.9 mg/kg/day) was very well tolerated without meaningful adverse effects. Atomoxetine significantly reduced core symptoms of ADHD (ADHD-Rating Scale-IV; 38.6% decrease vs. baseline, p < 0.001) with significant improvement (p < 0.05) in all but 1 of the 18 individual items in the ADHD-Rating Scale-IV. More than 75% of subjects who completed 10 weeks of treatment showed > 25% decrease in ADHD symptoms. CONCLUSIONS: These findings extend to children the positive results previously reported in adults diagnosed with ADHD who were treated with atomoxetine. These results support additional controlled trials of atomoxetine in cases of pediatric ADHD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnosis and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents
Goldman, L. S. (1998) · JAMA · doi:10.1001/jama.279.14.1100 · Cited by 1,082 · cited 2×
“…groups, about the abuse potential of stimulant drugs by the patient, family member, or his or her peers; the possibility of diversion; and safety concerns regarding the use of a controlled substance by patients who are impulsive and may be susceptible to antisocial tendencies (Goldman et al. 1998).”
Pharmacotherapy of Attention-Deficit Hyperactivity Disorder across the Life Cycle
SPENCER, T., BIEDERMAN, J., WILENS, T., HARDING, M., O'DONNELL, D., & GRIFFIN, S. (1996) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199604000-00008 · Cited by 830
Self-citationSpencer, T. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950180020004 · Cited by 402 · cited 2×
“Although tricyclic antidepressants have well-documented efficacy in the treatment of youths with ADHD, they have not been approved for the treatment of ADHD, and concerns regarding their safety have seriously limited their use (Biederman et al. 1995).”
Self-citationEffect of Anxiety on Cognition, Behavior, and Stimulant Response in ADHD
PLISZKA, S. R. (1989) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-198911000-00012 · Cited by 293 · cited 1×
“…ADHD children with depression and anxiety, 60% (6 of 10) reported a lesser response to stimulants in improving ADHD symptoms in children with comorbid mood and anxiety disorders (DuPaul et al. 1994; Pliszka 1989; Swanson et al. 1978; Tannock et al. 1995; Taylor et al. 1987; Voelker et al. 1983).”
A Controlled Clinical Trial of Bupropion for Attention Deficit Hyperactivity Disorder in Adults
Wilens, T. E., Spencer, T. J., Biederman, J., Girard, K., Doyle, R., Prince, J., Polisner, D., Solhkhah, R., Comeau, S., Monuteaux, M. C., et al. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.2.282 · Cited by 272
Self-citationSpencer, T., Biederman, J., Wilens, T., Faraone, S., Prince, J., Gerard, K., Doyle, R., Parekh, A., Kagan, J., & Bearman, S. K. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.8.775 · Cited by 250 · cited 3×
“…is closely matched between children and adults with ADHD to anti-ADHD medications, including stimulants–methylphenidate (Spencer et al. 1995), pemoline (Wilens et al. 1999a), and Adderall (Spencer et al. 2001)—and nonstimulants—bupropion (Wilens et al. 1999b) and desipramine (Wilens et al. 1996).”
Self-citation(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.9.1147 · Cited by 228 · cited 3×
“1999b) and desipramine (Wilens et al. 1996).”
Self-citationSwanson, J., Kinsbourne, M., Roberts, W., & Zucker, K. (1978) · PEDIATRICS · doi:10.1542/peds.61.1.21 · Cited by 205 · cited 1×
“…ADHD children with depression and anxiety, 60% (6 of 10) reported a lesser response to stimulants in improving ADHD symptoms in children with comorbid mood and anxiety disorders (DuPaul et al. 1994; Pliszka 1989; Swanson et al. 1978; Tannock et al. 1995; Taylor et al. 1987; Voelker et al. 1983).”
Cited by
Bymaster, F. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00346-9 · Cited by 1,123
Michelson, D., Allen, A. J., Busner, J., Casat, C., Dunn, D., Kratochvil, C., Newcorn, J., Sallee, F. R., Sangal, R. B., Saylor, K., et al. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.11.1896 · Cited by 599
Ten-Year Review of Rating Scales. V: Scales Assessing Attention-Deficit/Hyperactivity Disorder
COLLETT, B. R., OHAN, J. L., & MYERS, K. M. (2003) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000070245.24125.b6 · Cited by 514
Newcorn, J. H., Kratochvil, C. J., Allen, A. J., Casat, C. D., Ruff, D. D., Moore, R. J., Michelson, D., & Atomoxetine/Methylphenidate Comparative Study Group (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.05091676 · Cited by 336
“The margin of 15% was based on the estimated difference between methylphenidate and placebo seen in two previous atomoxetine studies (4, 22 ) using criteria set by regulatory authorities for equivalence studies (23).”
MethodBiederman, J., Melmed, R. D., Patel, A., McBurnett, K., Konow, J., Lyne, A., Scherer, N., & for the SPD503 Study Group (2008) · Pediatrics · doi:10.1542/peds.2006-3695 · Cited by 317
Self-citation
Metadata
- Authors
- Spencer, T., Biederman, J., Heiligenstein, J., Wilens, T., Faries, D., Prince, J., Faraone, S. V., Rea, J., Witcher, J., & Zervas, S.
- Venue
- Journal of Child and Adolescent Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2001-09
- Volume
- 11
- Issue
- 3
- Pages
- 251-265
- ISSN
- 1044-5463 (ISSN-L)
- 1557-8992
- OpenAlex
- W2083338868
- Cited by
- 147
- References
- 8
- FWCI
- 8.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An Open-Label, Dose-Ranging Study of Atomoxetine in Children with Attention Deficit Hyperactivity Disorder. https://app.cochat.ai/papers/10.1089/10445460152595577
- The paper
- Spencer, T., Biederman, J., Heiligenstein, J., Wilens, T., Faries, D., Prince, J., Faraone, S. V., Rea, J., Witcher, J., & Zervas, S. (2001). An Open-Label, Dose-Ranging Study of Atomoxetine in Children with Attention Deficit Hyperactivity Disorder. Journal of Child and Adolescent Psychopharmacology. https://doi.org/10.1089/10445460152595577
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.